Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQLJ3Y)

• Drug Name: DQP-1105 Drug Info
• Synonyms: KB-272091

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 76849261
  TTD Drug ID: DMQLJ3Y

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2D (GluN2D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[2]
D-aspartic acid	DM7Z892	Discovery agent	N.A.	Investigative	[2]
[3H]CPP	DMR5UBF	Discovery agent	N.A.	Investigative	[2]
2-Methylamino-succinic acid(NMDA)	DMKP6BM	Discovery agent	N.A.	Investigative	[2]
[3H]MDL105519	DMPKGHB	Discovery agent	N.A.	Investigative	[2]
[3H]CGP39653	DMITR7A	Discovery agent	N.A.	Investigative	[2]
homoquinolinic acid	DMBW5DU	Discovery agent	N.A.	Investigative	[2]
[3H]dizocilpine	DMEC2PF	Discovery agent	N.A.	Investigative	[2]
CGP61594	DM8KFZH	Discovery agent	N.A.	Investigative	[2]
(RS)-(tetrazol-5-yl)glycine	DMYZCRF	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2C (GluN2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[3]
D-aspartic acid	DM7Z892	Discovery agent	N.A.	Investigative	[3]
[3H]CPP	DMR5UBF	Discovery agent	N.A.	Investigative	[3]
2-Methylamino-succinic acid(NMDA)	DMKP6BM	Discovery agent	N.A.	Investigative	[3]
[3H]MDL105519	DMPKGHB	Discovery agent	N.A.	Investigative	[3]
[3H]CGP39653	DMITR7A	Discovery agent	N.A.	Investigative	[3]
homoquinolinic acid	DMBW5DU	Discovery agent	N.A.	Investigative	[3]
[3H]dizocilpine	DMEC2PF	Discovery agent	N.A.	Investigative	[3]
CGP61594	DM8KFZH	Discovery agent	N.A.	Investigative	[3]
(RS)-(tetrazol-5-yl)glycine	DMYZCRF	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Glutamate receptor ionotropic NMDA 2B (NMDAR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[4]
ELIPRODIL	DMIOGZM	Multiple sclerosis	8A40	Phase 2	[5]
CP-101,606	DMIU19E	Parkinson disease	8A00.0	Phase 2	[6]
CERC-301	DMSABRI	Major depressive disorder	6A70.3	Phase 2	[7]
RGH-896	DMCHZAN	Peripheral neuropathy	8C0Z	Phase 2	[8]
MIJ821	DMN45RI	Major depressive disorder	6A70.3	Phase 2	[9]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[10]
Neu-2000	DMNJTLC	Cardiac arrest	MC82	Phase 1	[11]
EVT100	DMAKWQD	Major depressive disorder	6A70.3	Phase 1	[12]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 2B (NMDAR2B)	TTN9D8E	NMDE2_HUMAN	Modulator (allosteric modulator)	[1]
Glutamate receptor ionotropic NMDA 2C (GluN2C)	TT1M8OW	NMDE3_HUMAN	Modulator (allosteric modulator)	[1]
Glutamate receptor ionotropic NMDA 2D (GluN2D)	TT5POTG	NMDE4_HUMAN	Modulator (allosteric modulator)	[1]

References

• [1] Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458).
• [4] NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
• [5] 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
• [6] NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
• [7] Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
• [8] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [9] Clinical pipeline report, company report or official report of Cadent Therapeutics.
• [10] Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
• [11] Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.